TARSUS PHARMACEUTICALS INC (TARS)

US87650L1035 - Common Stock

36.35  +1.78 (+5.15%)

After market: 36.35 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

TARSUS PHARMACEUTICALS INC

NASDAQ:TARS (3/28/2024, 4:02:40 PM)

After market: 36.35 0 (0%)

36.35

+1.78 (+5.15%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.36B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TARS Daily chart

Company Profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 87 full-time employees. The company went IPO on 2020-10-16. The Company’s lead product candidate, TP-03, is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). The firm designs TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The company is also focused on investigating the development of product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Company Info

TARSUS PHARMACEUTICALS INC

15440 Laguna Canyon Road

Irvine CALIFORNIA 92618

P: 19494099820

CEO: Bobak Azamian

Employees: 87

Website: https://www.tarsusrx.com/

TARS News

News Image17 days ago - Market News VideoInvestors Grab TARS Even Cheaper Than Its Secondary Stock Offering
News Image23 days ago - Tarsus Pharmaceuticals, IncTarsus to Participate at Upcoming Investor Conferences
News Image23 days ago - Tarsus Pharmaceuticals, IncTarsus to Participate at Upcoming Investor Conferences

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...

News Image23 days ago - Tarsus Pharmaceuticals, IncTarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
News Image23 days ago - Tarsus Pharmaceuticals, IncTarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease ...

News Imagea month ago - Seeking AlphaTarsus Pharmaceuticals stock dips after pricing $100M securities offering (NASDAQ:TARS)

Tarsus Pharmaceuticals faces a 10% premarket drop as it prices a $100M securities offering, consisting of shares and pre-funded warrants.

TARS Twits

Here you can normally see the latest stock twits on TARS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example